Compugen Ltd. (CGEN)
CGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.98
-4.35% on the day
Market cap
$187.3M
Micro cap
Revenue · 2025
$72.8M
+161.1% on 2024
Net income · 2025
$35.3M
48.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | 2000 |
| SEC CIK | 0001119774 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.8M |
| Net income | $35.3M |
| Operating income | $31.3M |
| Net margin | 48.6% |
| Operating margin | 43.1% |
| Revenue growth | +161.1% |
| Cash | $90.6M |
| Total assets | $156.6M |
| P/E (computed) | 5.3× |
| P/S (computed) | 2.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-05-18 |
| Latest annual report | 20-F | 2026-03-02 |
| Latest quarterly / interim | 6-K | 2026-09-10 |
Source: SEC EDGAR submissions feed, 607 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
| STRO | Sutro Biopharma Inc. | $11.01 | -17.09% | $182.6M |
| DTIL | Precision BioSciences Inc. | $6.10 | -6.58% | $168.4M |
| ALEC | Alector Inc. | $1.87 | -10.10% | $208.8M |
| CHRS | Coherus Oncology Inc. | $1.07 | +3.88% | $165.3M |
| IPHA | Innate Pharma S.A. ADS | $1.47 | -0.68% | $164.2M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $2.75 | -1.08% | $221.6M |
| LXEO | Lexeo Therapeutics Inc. | $2.74 | -9.87% | $224.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier